-
公开(公告)号：US20240024275A1
公开(公告)日：2024-01-25
申请号：US18144890
申请日：2023-05-09
Applicant: Alkermes Pharma Ireland Limited
Inventor： Tarek A. Zeidan , Scott Duncan , Christopher P. Hencken , Thomas Andrew Wynn , Carlos N. Sanrame
IPC: C07C233/90
CPC classification number: C07C233/90
Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
-
2.发明申请
公开(公告)号：US20200017529A1
公开(公告)日：2020-01-16
申请号：US16508697
申请日：2019-07-11
Applicant: Alkermes Pharma Ireland Limited
Inventor： Brian M. Aquila , Hoan Huynh , Lewis D. Pennington , Ingo Mugge , Baudouin Gerard , Markus Haeberlein , Roman A. Valiulin , Julius F. Remenar , Demetri T. Moustakas , Thomas Andrew Wynn , Todd Bosanac
IPC: C07D519/00 , A61K9/00
Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
-
公开(公告)号：US20190201367A1
公开(公告)日：2019-07-04
申请号：US16145703
申请日：2018-09-28
Applicant: Alkermes Pharma Ireland Limited
Inventor： Tarek A. Zeidan , Scott Duncan , Christopher P. Hencken , Thomas Andrew Wynn , Carlos N. Sanrame
IPC: A61K31/225 , C07D491/113 , C07D211/06 , C07D207/40 , C07D295/088 , C07D211/38 , C07C317/28 , C07C317/18 , C07D207/06 , C07C233/91 , C07C233/18 , C07C229/16 , C07C219/08 , C07D209/52
CPC classification number: A61K31/225 , C07C219/08 , C07C229/16 , C07C233/18 , C07C233/91 , C07C317/18 , C07C317/28 , C07D207/06 , C07D207/40 , C07D209/52 , C07D211/06 , C07D211/38 , C07D295/088 , C07D491/113
Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
-
公开(公告)号：US10117846B2
公开(公告)日：2018-11-06
申请号：US15704219
申请日：2017-09-14
Applicant: Alkermes Pharma Ireland Limited
Inventor： Tarek A. Zeidan , Scott Duncan , Christopher P. Hencken , Thomas Andrew Wynn , Carlos N. Sanrame
IPC: C07D491/113 , A61K31/225 , C07C317/28 , C07D211/38 , C07D295/088 , C07D207/40 , C07D211/06 , C07D207/06 , C07D209/52 , C07C317/18 , C07C219/08 , C07C229/16 , C07C233/18 , C07C233/91
Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
-
公开(公告)号：US20180064673A1
公开(公告)日：2018-03-08
申请号：US15704219
申请日：2017-09-14
Applicant: Alkermes Pharma Ireland Limited
Inventor： Tarek A. Zeidan , Scott Duncan , Christopher P. Hencken , Thomas Andrew Wynn , Carlos N. Sanrame
IPC: A61K31/225 , C07D491/113 , C07C317/18 , C07D207/40 , C07D295/088 , C07D211/38 , C07C317/28 , C07D209/52 , C07D207/06 , C07D211/06 , C07C219/08 , C07C233/91 , C07C233/18 , C07C229/16
CPC classification number: A61K31/225 , C07C219/08 , C07C229/16 , C07C233/18 , C07C233/91 , C07C317/18 , C07C317/28 , C07D207/06 , C07D207/40 , C07D209/52 , C07D211/06 , C07D211/38 , C07D295/088 , C07D491/113
Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
-
公开(公告)号：US20160326119A1
公开(公告)日：2016-11-10
申请号：US15216061
申请日：2016-07-21
Applicant: ALKERMES PHARMA IRELAND LIMITED
Inventor： Laura Cook Blumberg , Daniel R. Deaver , David J. Eyerman , Thomas Andrew Wynn
IPC: C07D221/28 , C07D405/06 , C07D221/26
CPC classification number: C07D221/28 , A61K31/485 , C07D221/26 , C07D405/06 , C07D489/00
Abstract: The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.
-
7.发明申请
公开(公告)号：US20140275205A1
公开(公告)日：2014-09-18
申请号：US14180687
申请日：2014-02-14
Applicant: ALKERMES PHARMA IRELAND LIMITED
Inventor： Tarek A. Zeidan , Scott Duncan , Christopher P. Hencken , Thomas Andrew Wynn , Carlos N. Sanrame
IPC: C07D207/12
CPC classification number: C07D491/113 , A61K31/4015 , C07C229/12 , C07C229/18 , C07C317/18 , C07C317/28 , C07D207/12 , C07D207/40 , C07D207/408 , C07D211/92 , C07D295/088
Abstract: The present invention provides compounds of formula (I), wherein: R1 is unsubstituted C1-C6 alkyl; La is substituted or unsubstituted C1-C6 alkyl linker, substituted or unsubstituted C3-C10 carbocycle, substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S; and R2 and R3 are each, independently, H, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C6-C10 aryl; or alternatively, R2 and R3, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S or a substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S. The invention also provides pharmaceutical compositions and methods for treating neurological diseases, such as multiple sclerosis.
Abstract translation: 本发明提供式（I）化合物，其中：R 1为未取代的C 1 -C 6烷基; La是取代或未取代的C 1 -C 6烷基接头，取代或未取代的C 3 -C 10碳环，含有一个或两个5-或6-元环和1-4个选自N，O和S的杂原子的取代或未取代的杂环， 包含一个或两个5-或6-元环和1-4个选自N，O和S的杂原子的未取代杂芳基; 且R 2和R 3各自独立地为H，取代或未取代的C 1 -C 6烷基或取代或未取代的C 6 -C 10芳基; 或者可选地，R 2和R 3与它们所连接的氮原子一起形成取代或未取代的杂芳基，其包括一个或两个5-或6-元环和1-4个选自N，O和S的杂原子或取代的 或未取代的杂环，其包含一个或两个5-或6-元环和1-4个选自N，O和S的杂原子。本发明还提供用于治疗神经疾病如多发性硬化的药物组合物和方法。
-
公开(公告)号：US20240300969A1
公开(公告)日：2024-09-12
申请号：US18409959
申请日：2024-01-11
Applicant: Alkermes Pharma Ireland Limited
Inventor： Scott Duncan , Tarek A. Zeidan , Christopher P. Hencken , Thomas Andrew Wynn , Carlos N. Sanrame
IPC: C07D491/113 , A61K31/4015 , C07C229/12 , C07C229/18 , C07C317/18 , C07C317/28 , C07D207/12 , C07D207/40 , C07D207/408 , C07D211/92 , C07D295/088
CPC classification number: C07D491/113 , A61K31/4015 , C07C229/12 , C07C229/18 , C07C317/18 , C07C317/28 , C07D207/12 , C07D207/40 , C07D207/408 , C07D211/92 , C07D295/088
Abstract: The present invention provides compounds of formula (I),
wherein:
R1 is unsubstituted C1-C6 alkyl;
La is substituted or unsubstituted C1-C6 alkyl linker, substituted or unsubstituted C3-C10 carbocycle, substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S; and
R2 and R3 are each, independently, H, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C6-C10 aryl;
or alternatively, R2 and R3, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S or a substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S.
The invention also provides pharmaceutical compositions and methods for treating neurological diseases, such as multiple sclerosis.
-
公开(公告)号：US11905298B2
公开(公告)日：2024-02-20
申请号：US17547118
申请日：2021-12-09
Applicant: Alkermes Pharma Ireland Limited
Inventor： Tarek A. Zeidan , Scott Duncan , Christopher P. Hencken , Thomas Andrew Wynn , Carlos N. Sanrame
IPC: C07C229/12 , C07D491/113 , A61K31/4015 , C07D207/40 , C07D207/12 , C07D207/408 , C07D211/92 , C07D295/088 , C07C229/18 , C07C317/18 , C07C317/28
CPC classification number: C07D491/113 , A61K31/4015 , C07C229/12 , C07C229/18 , C07C317/18 , C07C317/28 , C07D207/12 , C07D207/40 , C07D207/408 , C07D211/92 , C07D295/088
Abstract: The present invention provides compounds of formula (I), wherein:
R1 is unsubstituted C1-C6 alkyl;
La is substituted or unsubstituted C1-C6 alkyl linker, substituted or unsubstituted C3-C10 carbocycle, substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S; and
R2 and R3 are each, independently, H, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C6-C10aryl;
or alternatively, R2 and R3, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S or a substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S.
The invention also provides pharmaceutical compositions and methods for treating neurological diseases, such as multiple sclerosis.
-
公开(公告)号：US20230158017A1
公开(公告)日：2023-05-25
申请号：US18056975
申请日：2022-11-18
Applicant: Alkermes Pharma Ireland Limited
Inventor： Laura Cook Blumberg , Daniel R. Deaver , David J. Eyerman , Thomas Andrew Wynn
IPC: A61K31/485 , C07D211/62 , C07D217/04 , C07D221/22 , C07D221/28 , C07D223/04 , C07D401/12 , C07D405/12 , C07D489/00 , C07D489/09
CPC classification number: A61K31/485 , C07D211/62 , C07D217/04 , C07D221/22 , C07D221/28 , C07D223/04 , C07D401/12 , C07D405/12 , C07D489/00 , C07D489/09
Abstract: The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.
